Skip to main content
. 2011 Sep 6;90(5):540–552. doi: 10.1038/icb.2011.71

Figure 1.

Figure 1

ISCOMATRIX adjuvant activates innate immune cells in vivo. (a) Immune cell infiltrates were gated on the myeloid marker CD11b. Monocyte (CD11b+Ly6C+) and neutrophil (CD11b+Gr1+) recruitment into subcutaneous air-pouches was evaluated 4, 16 and 24 h following subcutaneous ISCOMATRIX adjuvant (IMX) administration. Profiles are representative for n=3–6 mice per time-point. (b) Levels of IL-5, monocyte chemotactic protein-1 α and macrophage CSF (macrophage-CSF) detected in cultured air-pouch immune exudates. Error bars show the s.e.m. (n=3 per group). Student's t-test was used to calculate statistical significance. (c) Time-course of NK cell accumulation in the DLN (brachial) and non-DLN (inguinal) following subcutaneous IMX injection. (d) Ex vivo NK cell IFN-γ production in the DLN and non-DLN after IMX administration. Error bars represent the s.e.m. (n=4–8 individual LN per time-point). (e) Representative profiles showing NK cell expression of CD69 in the DLN of naïve or 24 h after IMX injection. No increase in CD69 expression was observed on NK cells, or other cell populations, from the non-DLN (data not shown). All results are representative of at least two independent experiments.